Arteriovenous Graft Market Report: Trends, Forecast and Competitive Analysis to 2035

Arteriovenous Graft Market

The future of the global arteriovenous graft market looks promising with opportunities in the hemodialysis and surgical procedure markets. The global arteriovenous graft market is expected to reach an estimated $902 million by 2035 from $593 million in 2027 with a CAGR of 8.6% from 2027 to 2035. The major drivers for this market are the increase in hemodialysis procedure, the rising awareness regarding early dialysis access creation, and the growing adoption of advanced vascular graft materials.

• Lucintel forecasts that, within the type category, synthetic grafts is expected to witness higher growth over the forecast period due to more availability and durability of synthetic graft materials.
• Within the application category, hemodialysis is expected to witness higher growth over the forecast period due to increasing numbers of patients requiring lifelong hemodialysis.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increase of the incidence of chronic kidney disease as well as the number of dialysis centers.

Emerging Trends in Arteriovenous Graft Market

The arteriovenous graft market is expected to transition from traditional vascular conduits, and toward grafts which are resistant to infection and incorporation of individual patient's details, during the period of 2025-2027. The largest market opportunity will be created by the overall incidence of End-Stage Renal Disease (ESRD) and Dialysis. The focus of End-Stage Renal Disease Programs (ESRD Programs) is to improve the efficacy of Vascular Access (VA) and minimize the number of revisions. Lucintel predicts the key competition drivers will be patient-specific technologies and regional manufacturing.

• Infection-resistant Materials: There is an ongoing trend towards utilizing antimicrobial and heparin-bonded graft surfaces. The 2024 USRDS report estimated that the overall incidence of ESRD was 804,300. Given the continual rise in ESRD, there will be an increasing emphasis on the duration of Access and the number of Hospitalizations. Therefore, it is probable that Access manufacturers will shift their focus toward the production of more durable Access devices in the ensuing years.
• Improved Cannulation: The focus of the manufacture of dialysis grafts is to provide access for hemodialysis within a specified time period. The use of early-cannulation grafts in combination with a revised protocol for the immediate initiation of dialysis is likely to gain acceptance in the years 2025-2030.
• Patient-specific Planning: The use of 3-D imaging and computer modelling is enabling anatomy-based graft selection. In 2026, 20% of centres are expected to include imaging in their plans for vascular access. Better alignment between the graft and the patient vasculature may minimize kinking and stenosis and could potentially extend the service life of the graft.
• Manufacturing: Recent process automation in the production of textiles used in vascular grafts has allowed for improved uniformity. Further, the automation of a final inspection of the grafts have allowed for increased consistency in the production of vascular grafts. 2025-2027, anticipated increases in production of these grafts will allow for improved standardization and access within the health care system.
• Supply Chain: Manufacturers of vascular grafts are making efforts to eliminate reliance on a single supplier for raw materials and sterilization. In addition, 2025 anticipated changes in procurement will allow hospitals to have greater control over the products implanted in patients.

In the coming years, there is expected to be a greater focus by both manufacturers and health care systems on the clinical outcomes of procedures, rather than the number of procedures performed. This should create opportunities for manufacturers of vascular grafts to differentiate themselves in the market.

Recent Developments in the Arteriovenous Graft Market

The arteriovenous graft market is expected to become more active from 2025-2027, as demand from dialysis facilities for reliable vascular access increases. Additionally, graft manufacturers focus on innovation to achieve grafts with infection-resistant properties. According to Lucintel, the future of the market will focus on the durability of engineered grafts and the overall economy of vascular access. Regulatory hurdles have eased, allowing advancements in vascular grafts to rapidly move through the approval process.

• Approval of A Bioengineered Vascular Graft: In December 2024, the FDA approved the first human use of a bioengineered vascular graft, Symvess (Humaair), manufactured by Humacyte. It is expected that other vascular grafts manufactured through similar bioengineering processes will gain approval in the next 3 to 5 years.
• Continued Advancements By Gore: The Acuseal platform of Gore gained significant attention in the market due to the innovative infection-resistant grafts. The platform further focuses on achieving vascular access grafts which allow for immediate cannulation.
• Consolidation in The Dialysis Industry: With 4,000+ dialysis clinics reported by Fresenius Medical Care in February 2025, the consolidation in the industry is evident. There is a risk that the standardization of dialysis devices will be determined by a small number of companies. In such cases, centralized purchasing will lead suppliers to enhance the devices and strive for lower intervention rates and more dependable and reliable performance.
• Partnerships for Clinical Research: Several collaborative studies, sponsored by the Society for Vascular Access (SVA), for evaluating vascular access-related outcomes (e.g. patient-level graft patency and thrombectomy) gained momentum in 2025. Unlike in the past, when a surgeon's preference determined the type of dialysis access, comparative effectiveness data will be the key driver for adding/removing a product from the hospital formulary.
• Reshoring and Supply Chain Resiliency: Disruptions in the global supply chain during the COVID-19 pandemic prompted medical device manufacturers to re-evaluate their supply chains and focus on producing medical devices with raw materials from first and second tiers supplier. There were several public disclosures by device manufacturers during the first quarter of 2025 of significant investments for new manufacturing facilities. The new facilities, when operational, are expected to reduce the lead time for medical device availability and improve access to dialysis in emerging markets.

Considering the above, durable hemodialysis access will be the key driver of growth for medical device manufacturers in the coming years. Long-term evidence demonstrating a reduction in access-related interventions will drive preference for a particular access device. Reimbursement and other policy changes will require medical device manufacturers to lower the cost of access-related care and improve access-related outcomes.

Strategic Growth Opportunities in the Arteriovenous Graft Market

The dialysis population is growing, access failure is costly, and existing arteriovenous (AV) fistulas fail to meet the requirements for hemodialysis. Lucintel expects opportunities for device and access improvements from 2024 to 2026. Demand for improved vascular access will increase due to growing population needing renal replacement therapy.

• Early Cannulation Grafts: With the U.S. renal replacement therapy population estimated to be over 800,000 (as of January 2025, per USRDS data), there is increasing demand to move patients to dialysis and eliminate their reliance on central venous catheters. Purchasing will favour products that shorten hospital stays and accelerate time to dialysis.
• Infection-Resistant and Drug-Eluting Grafts: Antimicrobial and antithrombotic features, if effective in reducing thrombosis and access re-obstruction, can justify increased product cost. Bloodstream infections in the dialysis population, according to the June 2025 CDC report, remain of significant concern. Over the next several years, similar focus will be placed on reducing access related infections.
• Ambulatory Dialysis Access Solutions: Beyond the cost of the graft, procedures to create vascular access are recurring revenue opportunities. Medicare estimates that in February 2025, it covered more than 7 million patients for end-stage renal disease. Manufacturers are investing in outpatient vascular access procedures and surgical centers, which are more profitable if located near a concentration of dialysis patients.
• Emerging Markets: Suppliers can base their expansion in Latin America, the Middle East, and Southeast Asia on strategic alliances with dialysis service providers. In April 2025, Fresenius Medical Care had about 4,000 dialysis clinics. Graft manufacturers can be successful by focusing on high catheter dependence regions.
• Individualized Graft Design: Image-based measurements can help address difficult anatomical situations. Manufacturers can improve the design of vascular access grafts by using 3D printing to prototype vascular accessories. Over the next few years, individualized design can help address vascular access in difficult situations.

Focusing on improving workflow, particularly in the areas of infection control and time to first cannulation, gives vascular graft manufacturers the opportunity to differentiate their products. Recent trends in the vascular graft industry suggest that in the coming years, manufacturers that build evidence-based clinical practices and services, and invest in regional service and support, will capture higher-margin markets. Purchasing teams at dialysis clinics will evaluate whole-treatment cost impact, and will consider graft price differently.

Arteriovenous Graft Market Drivers and Challenges

Advances in medical technology have resulted in greater options for treatment of end stage renal disease. However, several constraints, including risks associated with the use of medical devices, attitudes of the medical fraternity, and direct and indirect costs, have limited the widespread adoption of medical devices for vascular access.

The factors responsible for driving this market include:

• Increase in The Number of Patients Suffering from End-stage Renal Disease: Rising levels of diabetes and hypertension, obesity, and aging have resulted in an increase in the number of patients requiring renal replacement therapy. As per the latest estimates available from the center for Medicare and Medicaid Services, the number of individuals in the US suffering from end stage renal disease was in excess of 800,000. With the expanding target population, there has been an increased emphasis on the creation of vascular access. A large portion of the patients are not ideal candidates for the creation of fistulas. In addition, vascular access may be required for plasmapheresis and chronic blood transfusions. With the increasing incidence and awareness of renal and other diseases, it is likely that the need for vascular access will also increase.
• Technological Developments: Improvements in the manufacturing and surface coating of biomaterials reduce complications and enhance their functionality. In 2025, numerous ongoing studies of antimicrobial and other advanced vascular grafts technologies were being conducted. It is anticipated that with advanced biomaterials, therapies to treat vascular diseases would progressively become less invasive and improve recovery.
• Investments in Health Care: The new facilities improved access to vascular surgery. Global investments in health care in 2025 exceeded $1 trillion, and new vascular access centres and dialysis facilities increased access to surgical care. New vascular surgery centres fostered competition, stimulated the development of new vascular access products, and enhanced global surgical teams. Initiatives to reduce the cost of hemodialysis, improve the accessibility of surgery, enhance graft quality and availability, especially in underserved areas, and foster regional and public-private partnerships would positively impact vascular health care.
• Product Development: Factors such as flexibility, cannulation, and kinking have influenced the development of vascular grafts. Other considerations have included grafts' ability to conform to the body, and their overall size. As these factors continue to improve, the ability of grafts to support the body and maintain a patent lumen will also likely improve. Along with the ongoing advancement of prosthetics, increased collaboration between manufacturers and institutions will allow the development of specialized vascular grafts. This specialization, as well as the increased focus on patency, will give healthcare providers more options when treating vascular diseases and conditions.
• Efficiency and Cost Effectiveness: There is a growing body of research and evidence that the development of better vascular grafts and the advancement of procedures to utilize them will lead to increased cost-effectiveness and improvements in healthcare. Research suggests that the greatest difference in cost will stem from a reduction in access revascularization procedures. Value-based health insurance reimbursement, and the increased focus of healthcare on reducing costs while improving quality, will reward the development of the best vascular grafts and related prosthetics.

The challenges facing this market include:

• Infection and Thrombosis Risks: Thrombosis and infection are the most prevalent complications of AVGs. Stenosis and thrombosis lead to access failure and require repeated punctures. Complications of AVG increase the duration of hospital stays, increase the need for antibiotic therapy and surgery. The reviewed literature from 2025 reported infections between 5 to 20 percent. The presence of infection increases the risk of patient mortality. Over the next 3 to 5 years, it is expected that infection and thrombosis will continue to pose a major challenge to AVGs. To reduce these complications, the introduction of new technologies to improve surveillance and provide antimicrobial surfaces will be necessary. The preference for a vascular access method will be determined by the perceived complications.
• Competition from AV Fistulas and Catheters: AV fistulas and catheters provide vascular access for hemodialysis. In 2025, AV fistulas accounted for more than 50 percent of all hemodialysis access in the U.S. Fistulas and catheters present a barrier for use of AVGs. The use of AVGs is restricted to patients who are unable to form AV fistulas and/or in patients who require immediate dialysis. In the next 3 to 5 years, ongoing improvement in fistula first strategies will continue to provide a barrier for AVGs. In order to increase use of AVGs, evidence to support its use in high risk patients will be needed.
• Regulatory and Reimbursement Environment: Effective January 2026, new criteria require that all vascular grafts demonstrated improved safety, reduced infection, and improved clinical performance. The changes are expected to result in lengthier approval processes. Beyond these changes, manufacturers must contend with price ceilings and ongoing negotiations for reimbursement, constrained hospital budgets, and raw material costs. Supply and demand issues have affected the market, resulting in reduced adoption of new products. These conditions are expected to continue, and in the next three to five years, new regulatory requirements are expected to increase.

There are many positive factors influencing the arteriovenous gust market including the increase in the number of end stage renal disease patients requiring dialysis, as well as improved and innovative biomaterials. Improved and more accessible vascular access is likely to stimulate the market. Fistulas are preferred over synthetic vascular grafts; however, not all patients are eligible for fistulas. Also, vascular grafts are subject to infection and thrombosis. The market will experience the strongest growth in complex, high-skill access, and unmet clinical need.

List of Arteriovenous Graft Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies arteriovenous graft market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the arteriovenous graft market companies profiled in this report include-

• Getinge Group
• BD
• Terumo
• B.Braun
• LeMaitre

Arteriovenous Graft Market by Segment

The study includes a forecast for the global arteriovenous graft market by type, application, and region.

Arteriovenous Graft Market by Type [Value ($M) from 2019 to 2035]:

• Synthetic Grafts
• Biological Grafts

Arteriovenous Graft Market by Application [Value ($M) from 2019 to 2035]:

• Hemodialysis
• Surgical Procedures
• Others

Arteriovenous Graft Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Arteriovenous Graft Market

From 2025 to 2027, the policy related to dialysis access, the state of domestic medical device manufacturing, and advances in vascular access technology will impact medical device procurement. Trends in supplier performance will be determined by the quality and availability of clinical data and the regulation of medical devices.

• United States: From 2025 to 2027, changes in Medicare payment rates and the modernization of medical devices will occur. Hospital procurement of medical devices will depend on clinical evidence and the technology available to provide vascular access.
• China: China is building its domestic supply of medical devices and reorganizing how it purchases medical devices at the provincial level. In 2025, China's Food and Drug Administration (FDA) opened more pathways to register medical devices at the national level. Meanwhile, provincial procurement programs developed more stringent procedures to evaluate price and weigh local supply. Lifetech Scientific and Jiangsu Yuyue deepened their local production of cardiovascular medical devices in 2025. Lifetech reported 40 product registrations in 2024 and plans to further increase local production and competition for foreign devices.
• Germany: German medical device manufacturers concentrated on the forthcoming certification for market access under the EU Medical Device Regulation (MDR) and further customization of their medical device productions. Companies such as Aesculap, which manufactures surgical implants, continued serving hospitals in the EU. Aesculap reported global sales of 2.5 billion euros in 2024. Concentrated and customized production of grafts systems will influence the medical devices available in Germany and other EU countries.
• India: The Indian government organizes large procurement processes and initiates local manufacturing in different sectors. The Indian Ministry of Health stated that in 2025, over 1.3 million dialysis sessions were performed by the Indian government. As a result, local device manufacturers increased their focus on vascular access manufacturing. Additionally, government procurement of dialysis grafts is likely to facilitate the use of locally manufactured grafts and reduce the dependence on foreign conducts in the future.
• Japan: Access and Partnerships in Hospitals

The Japanese Society for Dialysis Therapy (JSDT) stated that in 2024, 340,000 patients in Japan underwent dialysis. Due to the large number of dialysis patients, Japanese hospitals and device manufacturers focused on improving and establishing durability of vascular access. Thus, improved vascular access grafts and sedentary dialysis remain in demand in Japan's dialysis market.

Features of the Global Arteriovenous Graft Market

• Market Size Estimates: arteriovenous graft market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: arteriovenous graft market size by type, application, and region in terms of value ($B).
• Regional Analysis: arteriovenous graft market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the arteriovenous graft market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the arteriovenous graft market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the arteriovenous graft market by type (synthetic grafts and biological grafts), application (hemodialysis, surgical procedures, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?